The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008)

Journal of Infection

Volumn 60, Issue 6, 2010, Pages 440-451

  Farrell, David J ^a   Turnidge, John D ^b   Bell, Jan ^b   Sader, Helio S ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; AUSTRALIA; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHINA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DILUTION; ENTEROBACTERIACEAE; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HONG KONG; IN VITRO STUDY; KLEBSIELLA; KOREA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEW ZEALAND; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PROTEUS PENNERI; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PUTIDA; PSEUDOMONAS STUTZERI; SINGAPORE; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; TAIWAN; THAILAND; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ASIA, SOUTHEASTERN; AUSTRALIA; DRUG RESISTANCE, BACTERIAL; FAR EAST; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; NEW ZEALAND; SENTINEL SURVEILLANCE;

EID: 77953325317     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.03.024     Document Type: Article

References (26)

1. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl. 5):S354-S367.
2. Bouchillon S.K., Hoban D.J., Johnson B.M., Johnson J.L., Hsiung A., Dowzicky M.J. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005, 52:173-179.
3. Bouchillon S.K., Iredell J.R., Barkham T., Lee K., Dowzicky M.J. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents 2009, 33:130-136.
4. CTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist 2008, 14:211-216.
5. CLSI Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2009, Clinical and Laboratory Standards Institute, Wayne, PA, M07-A8. 8th ed.
6. CLSI Performance standards for antimicrobial susceptibility testing 2009, 19th Informational supplement, Clinical and Laboratory Standards Institute, Wayne, PA, M100-S19.
7. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42(Suppl. 2):S82-S89.
8. Dean C.R., Visalli M.A., Projan S.J., Sum P.E., Bradford P.A. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003, 47:972-978.
9. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl. 5):S341-S353.
10. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., Jones R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis 2005, 52:195-201.
11. Fritsche T.R., Strabala P.A., Sader H.S., Dowzicky M.J., Jones R.N. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005, 52:209-213.
12. Gales A.C., Sader H.S., Fritsche T.R. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008, 60:421-427.
13. Hirakata Y., Matsuda J., Miyazaki Y., Kamihira S., Kawakami S., Miyazawa Y., et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005, 52:323-329.
14. Hoban D.J., Bouchillon S.K., Johnson B.M., Johnson J.L., Dowzicky M.J. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005, 52:215-227.
15. Jones R.N., Ferraro M.J., Reller L.B., Schreckenberger P.C., Swenson J.M., Sader H.S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007, 45:227-230.
16. Ko K.S., Song J.H., Lee M.Y., Park S., Kwon K.T., Heo S.T., et al. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries. Diagn Microbiol Infect Dis 2006, 55:337-341.
17. Lode H.M. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin Microbiol Infect 2009, 15:212-217.
18. Mendes R.E., Kiyota K.A., Monteiro J., Castanheira M., Andrade S.S., Gales A.C., et al. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol 2007, 45:544-547.
19. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999, 43:738-744.
20. Roberts M.C. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev 1996, 19:1-24.
21. Rodriguez-Bano J., Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther 2008, 6:671-683.
22. Sader H.S., Jones R.N., Stilwell M.G., Dowzicky M.J., Fritsche T.R. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005, 52:181-186.
23. Song J.H., Hiramatsu K., Suh J.Y., Ko K.S., Ito T., Kapi M., et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004, 48:4926-4928.
24. Song J.H., Jung S.I., Ko K.S., Kim N.Y., Son J.S., Chang H.H., et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004, 48:2101-2107.
25. Tanaseanu C., Milutinovic S., Calistru P.I., Strausz J., Zolubas M., Chernyak V., et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009, 9:44.
26. Tygacil 2009, Wyeth Pharmaceuticals, Philadelphia, PA.